CHICAGO, Nov. 26, 2023 /PRNewswire/ - Densitas Inc., a global leader in artificial intelligence solutions for breast cancer screening, today announced a partnership with CancerIQ, a precision cancer prevention platform, to expand its offering to include CancerIQ's Tyrer-Cuzick 8 risk calculator, as well as its care management and patient activation capabilities.
With this partnership, Densitas will offer CancerIQ's Tyrer-Cuzick 8 risk calculator alongside its mammography quality AI platform to enable clinicians to easily assess patient lifetime risk and current breast health, generate payer-supported risk-based care plans, and provide the patient education and navigation support needed for long-term adherence.
"Our collaboration with CancerIQ reflects our commitment to furnishing care providers with best-in-class solutions for breast health," said Mo Abdolell, founder and CEO, Densitas. "We are delighted to count CancerIQ with their industry-leading expertise and innovative familial and genetic risk platform that more than doubles adherence to screening, among our elite circle of premier industry partners, supporting the provision of peerless mammography quality and ultimately saving more lives."
Densitas offers a robust AI-driven mammography quality assurance platform that comprises intelliMammo® and intelliMaven™. intelliMammo® is built on deep learning and machine learning algorithms that assess clinical image quality and breast density for advanced analytics and workflow functions. Complementing this is intelliMaven™, the first-ever and only generative AI application for quality assurance. This integrated platform provides mammography facilities and clinical care teams with a comprehensive and scalable solution that boosts operational efficiency, improves mammography quality, and increases clinical confidence. Importantly, it ensures compliance with the FDA's Mammography Quality Standards Act (MQSA) EQUIP and the American College of Radiology's standards.
intelliMammo® helps reduce clinical image quality error rates by as much as 44%, and enables compliance with key MQSA EQUIP and adherence to ACR accreditation requirements in mere seconds and minutes, as opposed to days and weeks. intelliMaven™ aids radiological technologists to increase their clinical confidence and autonomy, which buffers radiologists from disruptions during the interpretation of mammography exams.